1. 暨南大学附属第一医院
2. 暨南大学医学院
纸质出版:2013
移动端阅览
[1]孙升云,金鑫,黄少君,徐梅,颜显欣,朱诗平,何玲,聂玲辉.慢肾康宁对肾间质纤维化大鼠内质网应激PERK-ATF4通路的影响[J].中医杂志,2013,54(03):236-240.
SUN Shengyun1, JIN Xin1, HUANG Shaojun2, et al. Effect of Manshen Kangning Formula on PERK/ATF4 Pathway in Endoplasmic Reticulum Stress in Renal Interstitial Fibrosis Rats[J]. Journal of Traditional Chinese Medicine2013, 54(3): 236-240.
[1]孙升云,金鑫,黄少君,徐梅,颜显欣,朱诗平,何玲,聂玲辉.慢肾康宁对肾间质纤维化大鼠内质网应激PERK-ATF4通路的影响[J].中医杂志,2013,54(03):236-240. DOI: 10.13288/j.11-2166/r.2013.03.025.
SUN Shengyun1, JIN Xin1, HUANG Shaojun2, et al. Effect of Manshen Kangning Formula on PERK/ATF4 Pathway in Endoplasmic Reticulum Stress in Renal Interstitial Fibrosis Rats[J]. Journal of Traditional Chinese Medicine2013, 54(3): 236-240. DOI: 10.13288/j.11-2166/r.2013.03.025.
目的探讨慢肾康宁对肾间质纤维化大鼠肾脏组织的保护作用及机制。方法 60只雄性Wistar大鼠
随机选取7只为正常组
其余53只采用2.5%腺嘌呤悬浮液灌胃建立肾间质纤维化模型
21d后将50只造模成功的大鼠随机分为模型组、氯沙坦组[10mg/(kg·d)]、慢肾康宁低剂量组[7.5g/(kg·d)]、慢肾康宁中剂量组[15g/(kg·d)]、慢肾康宁高剂量组[30g/(kg·d)]
每组10只
分别给予相应药物灌胃
正常组和模型组以等量蒸馏水灌胃
连续30d。实验结束后
检测各组大鼠血清肌酐(SCr)、尿素氮(BUN)、24小时尿蛋白定量(24hMTP)
估算肾小球滤过率(eGFR)
HE和Masson染色观察肾组织病理变化
免疫组织化学方法检测肾组织内质网应激标志性蛋白葡萄糖调节蛋白78(GRP78)
TUNEL法检测肾小管上皮细胞凋亡水平
实时定量PCR测定肾组织GRP78、转录激活因子4(ATF4)、CCAAT增强子结合蛋白同源蛋白(CHOP)mRNA表达水平。结果与模型组比较
氯沙坦组和慢肾康宁各剂量组SCr、BUN、24hMTP均显著下降(P<0.01)
eGFR上升(P<0.01)。病理观察
模型组可见肾小管上皮细胞凋亡、坏死、脱落
肾小管扩张、炎性细胞浸润
肾间质内腺嘌呤代谢产物沉积和胶原纤维增生
氯沙坦组和慢肾康宁各组较模型组病理变化轻。与模型组比较
各给药组GRP78表达水平及细胞凋亡水平均下降(P<0.05或P<0.01)。各给药组GRP78、ATF-4、CHOPmRNA表达水平较模型组降低(P<0.05)。结论慢肾康宁对肾间质纤维化大鼠肾脏组织内质网应激PERK-eIF2α-ATF4-CHOP通路过度表达有很好的抑制作用
具有肾脏保护功能
这可能是它减轻肾间质纤维化的重要机制之一。
Objective To observe the effect and mechanism of Manshen Kangning Formula(formula for chronic kidney disease
MKF)on endoplasmic reticulum stress in renal tissue of renal interstitial fibrosis rats.Methods Sixty male Wistar rats were selected
seven wererandomly set into normal group
and other 53were given 2.5%adenine to make renal interstitial fibrosis model.After modeling
fifty successful model rats were randomized into model group
losartan group
MKF small-dose group
MKF middle-dose group and MKF large-dose group
with 10in each.The treatment groups were given losartan suspension[10mg/(kg·d)]
small-dose MKF suspension[7.5g/(kg·d)]
middle-dose MKF suspension[15g/(kg·d)]and large-dose MKF suspension[30g/(kg·d)]respectively and the same amount of distilled water was given to the normal group and model group intragastrically.The administration lasted for 30days.The serum creatinine(SCr)
blood urea nitrogen(BUN)
24-hour urinary protein(24hUP)and estimated glomerular filtration rate(eGFR)were detected.The renal histopathological changes were observed with HE and Masson staining.The glucose-regulated protein 78(GRP78)was detected with immunohistochemical staining and the apoptotic cells were detected with TUNEL staining.Real Time PCR was used to detect the expression levels of GRP78mRNA
activating tranSCription factor 4(ATF4)mRNA and CCAAT/enhancer-binding protein homologous protein(CHOP)mRNA.Results Comparing with the model group
the levels of SCr
BUN and 24hUP were significantly decreased(P<0.01)
but the eGFRs were significantly increased in the losartan group and MKF groups(P <0.01).Apoptosis
necrosis and shedding in renal tubular epithelial cells
tubular dilatation
inflammatory cell infiltration
adenine metabolite deposition and collagen fibers in renal interstitial tissue could be seen under the microscope in the model group.Comparing with the model group
the pathological changes were lighter in the losartan group and MKF groups.Comparing with the model group
GRP78expressions and apoptosis levels were significantly decreased in the losartan group and MKF large-dose group(P<0.05).Comparing with the model group
the expressions of GRP78mRNA
ATF-4mRNA and CHOP mRNA were significantly decreased(P<0.05).Conlcusion Endoplasmic reticulum stress is related to the occurrence and development of renal interstitial fibrosis.MKF can attenuate renal interstitial fibrosis and protect kidney function
which may be relevant to regulating the over expression of PERK-eIF2α-ATF4-CHOP pathway.
0
浏览量
505
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号